A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease
Sponsor: Agios Pharmaceuticals, Inc.
Principal Investigator: Bogdan Dumitriu, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection
Sponsor: Rebiotix
Principal Investigator: David Yoho, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

D/C/F/TAF FDC Evaluated as a Fixed Dose Combination Regimen in Participants Switching from an Integrase Inhibitor who have Experienced Rapid Weight Gain
Sponsor: Janssen Scientific Affairs, LLC
Principal Investigator: Michael Horberg, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

No Active Trials

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Sponsor: Southwest Oncology Group (SWOG)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES) S-0820
Sponsor: Southwest Oncology Group (SWOG)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

ALCHEMIST- Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Sponsor: Alliance for Clinical Trials in Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants with Advanced Solid Tumors
Sponsor: Arcus Biosciences, Inc.
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Sponsor: National Cancer Institute (NCI), Southwest Oncology Group (SWOG)
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Sponsor: Alliance for Clinical Trials in Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

Breast Cancer Weight Loss Study (BWEL Study)
Sponsor: Alliance for Clinical Trials in Oncology
Principal Investigator: Leon C Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Sponsor: National Cancer Institute (NCI), NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Sponsor: NRG Oncology
Principal Investigator: Leon C Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
Sponsor: Alliance for Clinical Trials in Oncology, American College of Radiology Imaging Network, National Cancer Institute (NCI)
Principal Investigator: Amadea Tette, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Sponsor: National Cancer Institute
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Sponsor: Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Sponsor: National Cancer Institute (NCI), NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Sponsor: ECOG-ACRIN Cancer Research Group
Principal Investigator: Ainsley Maclean, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

An Open-label, Non-randomized, Prospective Observational Cohort Study to Assess Post Procedural Outcomes in Two Cohorts of Women Who Chose to Undergo Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization
Sponsor: Bayer
Principal Investigator: Jill Finkelstein, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969

Phase II/III Study of Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Sponsor: National Cancer Institute (NCI), NRG / NRG Oncology
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969